0.85 USD
▼-0.01-7.30%
盘后 0.90 -2.22%
2026-08-03
市值
$10.08M
市盈率
—
EPS
-0.27
股息率
—
52 周区间
0.68 – 3.68
成交量
12.18K
Beta
0.02
目标价
—
52W 低 0.6852W 高 3.68
价格走势
公司简介
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural ...